(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israeli forces kill one person in series of attacks on southern Lebanon - 2Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- 3Parents speak out as 4-year-old fights button battery injury in intensive care unit
- 4Report in relation to renaming Herzog Park set to be withdrawn
- 5Exploring School Life: Self-awareness and Illustrations
- Investigating Inside Plan and Home Style: Change Your Residing Space
- 6 Home Cleaning Administrations to Keep Your Home Unblemished
- Employers and staff feel effect of fuel price rise
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- AfD faction in western Germany ousts councilman for firebrand speech
- Clocks to go forward one hour in Europe as summer time starts
- Pick Your #1 Kind Of Treat
- A Lone Wolf Outsmarted Hunters in the Black Forest and Then Vanished
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
